How do you assess and encourage adherence to adjuvant hormonal therapy in early stage breast cancer patients?  

Adherence is important to maximize the benefits of adjuvant therapy. Unfortunately studies that measure adherence (pill counts, bottle monitors, prescription records) suggest that many (as many as 40%) of patients discontinue therapy or take <85% of planned doses within the first 5 years. I ask o...

I agree with @Kathy Miller; adherence and persistence to endocrine therapy is a challenge in the management of HR+ breast cancer. I also use open-ended questions. Careful assessment of side effects is important, as I think they are the most common cause of discontinuation of endocrine therapy. While...